Searched for
CIPLA RESPIRATORY PRODUCTS
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosolPharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...
- Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ crCipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...
- Cipla targets $1 bn US revenue in FY27Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics ...
- Cipla, Kemwell Biopharma join hands to develop biosimilarsUnder the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product develo...
- Brokerages raise targets on CiplaCipla’s shares hit a record high of Rs 814.45 on Monday before ending at Rs 795.65, up 9.2 per cent from the previous close. Cipla reported...
- Over 200 drugs under development, top 50 with $30 billion potential: CiplaElaborating on the pipeline for new drugs, Cipla said it has over 200 drugs under development with the top 50 projects having potential of ...
- Cipla inks pact with Biopharma SPA to establish joint venture in AlgeriaCipla has inked a pact with Biopharma SPA for establishing a joint venture company in Algeria to manufacture and market respiratory product...
- Cipla to form joint venture with Biopharm SPA for respiratory productsCipla has entered into an agreement with Biopharm SPA to form a joint venture company in Algeria to manufacture and market respiratory prod...
- Cipla rallies over 1% on tie-up plans UK's S&D Pharma; top Sensex gainerCipla said this collaboration will enable it to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.
- Cipla announces commercial tie-up with UK's S&D PharmaPharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.
- Cipla unit gets 345 million rand contract from South AfricaUnder the contract, which will run from July 2014 to April 2017, the company will supply drugs including Beclate 100, Becalate 200 and Asth...
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...
Load More
